AcelRx Pharmaceuticals, Inc. / Financial strength (Piotroski F-Value) /

    The F-Value, developed by Stanford accounting professor Joseph Piotroski, measures a company's financial strength based on nine distinct criteria. Piotroski suggest using the value as part of a value investing strategy to rank stocks with a low price-to-book ratio. The approach is described in detail in Piotroski's 2002 Paper Value Investing: The Use of Historical Financial Statement Information to Separate Winners From Losers.

    You are viewing the F-Value as of . Click to view the current F-Value instead.

    Financial strength (Piotroski F-Value)
    3 / 9
    Return on assets (ROA) greater than 0
    close -48.9%
    Operating cash flow greater than 0
    close -$39.25M
    ROA greater than previous year
    check -48.9% > -57.2%
    Cash flow return on assets (CFROA) greater than Return on assets (ROA)
    check -43.8% > -48.9%
    Leverage ratio lower than previous year
    close 24.7% ≥ 7.1%
    Current ratio greater than previous year
    check 749.4% > 456.1%
    No new common stock issued last year
    close $46.02M
    Gross margin greater than previous year
    close -164.8% ≤ -62.4%
    Asset turnover greater than previous year
    close 2.3% ≤ 2.9%

    F-Value history

    The F-Value is calculated for each quarter based on the cumulation of the previous four quarterly statements. Click on the chart to see the F-Value at a specific time in the past.

    4
    4
    2
    2
    2
    3
    3
    3
    4
    6
    5
    5
    6
    0
    0
    1
    2
    5
    5
    5
    2
    2
    2
    2
    3
    2
    2
    3
    3
    4
    4
    3
    3
    2
    2
    3
    2
    4
    5
    4
    5
    4
    2
    5
    3
    4
    4
    3
    2
    3
    3
    5
    2
    2

    Notifications